Ultrasonic nanobubbles carrying anti-PSMA nanobody: Construction and application in prostate cancer-targeted imaging

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Fan, Xiaozhou ^a   Wang, Luofu ^a   Guo, Yanli ^a   Tu, Zhui ^b   Li, Lang ^a   Tong, Haipeng ^a   Xu, Yang ^b   Li, Rui ^a   Fang, Kejing ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; NANOBODY; NANOBUBBLE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; STREPTAVIDIN; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISSOCIATION CONSTANT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMAGE RECONSTRUCTION; IMMUNOFLUORESCENCE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; ULTRASOUND; ULTRAVIOLET SPECTROPHOTOMETRY; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; IMMUNOLOGY; METABOLISM; MOLECULAR IMAGING; PROCEDURES; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MICE; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTEIN BINDING; SINGLE-DOMAIN ANTIBODIES;

EID: 84938674623     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0127419     Document Type: Article

References (37)

1. Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM. Molecular imaging of prostate cancer. Methods. 2009; 48(2):193-9. doi: 10.1016/j.ymeth.2009.03.021 PMID: 19362147
2. Gessner R, Dayton PA. Advances in molecular imaging with ultrasound. Mol Imaging. 2010; 9(3):117-27. PMID: 20487678
3. Klibanov AL. Ultrasound molecular imaging with targeted microbubble contrast agents. J Nucl Cardiol. 2007; 14(6):876-84. PMID: 18022115
4. Moestue SA, Gribbestad IS, Hansen R. Intravascular targets for molecular contrast-enhanced ultrasound imaging. Int J Mol Sci. 2012; 13(6):6679-97. doi: 10.3390/ijms13066679 PMID: 22837657
5. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009; 71(3):409-19. doi: 10.1016/j.ejpb.2008.11.010 PMID: 19070661
6. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998; 95(8):4607-12. PMID: 9539785
7. Yin T, Wang P, Zheng R, Zheng B, Cheng D, Zhang X, et al. Nanobubbles for enhanced ultrasound imaging of tumors. Int J Nanomedicine. 2012; 7:895-904. doi: 10.2147/IJN.S28830 PMID: 22393289
8. Wang L, Li L, Guo Y, Tong H, Fan X, Ding J, et al. Construction and in vitro/in vivo targeting of PSMA-targeted nanoscale microbubbles in prostate cancer. Prostate. 2013; 73(11):1147-58. doi: 10.1002/pros.22663 PMID: 23532872
9. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008; 29(2):57-61. doi: 10.1016/j.tips.2007.11.004 PMID: 18179828
10. Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428):446-8. PMID: 8502296
11. De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as research and diagnostic tools. Trends in Biotechnology. 2014; 32(5):263-70. doi: 10.1016/j.tibtech.2014.03.001 PMID: 24698358
12. Siontorou CG. Nanobodies as novel agents for disease diagnosis and therapy. Int J Nanomed. 2013; 8:4215-27.
13. Oliveira S, Heukers R, Sornkom J, Kok RJ, Henegouwen PMPVE. Targeting tumors with nanobodies for cancer imaging and therapy. Journal of Controlled Release. 2013; 172(3):607-17. doi: 10.1016/j.jconrel.2013.08.298 PMID: 24035975
14. De Vos J, Devoogdt N, Lahoutte T, Muyldermans S. Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target. Expert Opin Biol Th. 2013; 13(8):1149-60.
15. Schoonooghe S, Laoui D, Van Ginderachter JA, Devoogdt N, Lahoutte T, De Baetselier P, et al. Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer. Immunobiology. 2012; 217(12):1266-72. doi: 10.1016/j.imbio.2012.07.009 PMID: 22884356
16. Vaneycken I, D'huyvetter M, Hernot S, De Vos J, Xavier C, Devoogdt N, et al. Immuno-imaging using nanobodies. Curr Opin Biotech. 2011; 22(6):877-81. doi: 10.1016/j.copbio.2011.06.009 PMID: 21726996
17. Fan XZ, Guo YL, Tu Z, Tong HP, Li L, Wang LF, et al. Eukaryotic expression of extracellular domain of prostate-specific membrane antigen and biopanning of its nanobodies. Journal of Third Military Medical University. 2013; 35(21): 2320-4.
18. Johnson-Neitman JL, O'Brien RT, Wallace JD. Quantitative perfusion analysis of the pancreas and duodenum in healthy dogs by use of contrast-enhanced ultrasonography. American Journal of Veterinary Research. 2012; 73(3):385-92. doi: 10.2460/ajvr.73.3.385 PMID: 22369531
19. Siegel R, Ma JM, Zou ZH, Jemal A. Cancer Statistics, 2014. Ca-Cancer J Clin. 2014; 64(1):9-29. doi: 10.3322/caac.21208 PMID: 24399786
20. Yossepowitch O, Eggener SE, Serio AM, Caruer BS, Bianco FJ, Scardino PT, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. European Urology. 2008; 53(5):950-9. PMID: 17950521
21. Matsumoto K, Nakagawa K, Hashiguchi A, Kono H, Kikuchi E, Nagata H, et al. Contrast-enhanced Ultrasonography of the Prostate with Sonazoid. Japanese Journal of Clinical Oncology. 2010; 40(11):1099-104. doi: 10.1093/jjco/hyq102 PMID: 20581002
22. Seitz M, Gratzke C, Schlenker B, Buchner A, Karl A, Roosen A, et al. Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urol Oncol-Semin Ori. 2011; 29(3):295-301.
23. Li YM, Tang J, Fei X, Gao Y. Diagnostic Performance of Contrast Enhanced Ultrasound in Patients with Prostate Cancer: A Meta-Analysis. Academic Radiology. 2013; 20(2):156-64. doi: 10.1016/j.acra.2012.09.018 PMID: 23103186
24. Deshpande N, Needles A, Willmann JK. Molecular ultrasound imaging: current status and future directions. Clinical Radiology. 2010; 65(7):567-81. doi: 10.1016/j.crad.2010.02.013 PMID: 20541656
25. Tardy I, Pochon S, Theraulaz M, Emmel P, Passantino L, Tranquart F, et al. Ultrasound Molecular Imaging of VEGFR2 in a Rat Prostate Tumor Model Using BR55. Investigative Radiology. 2010; 45 (10):573-8. doi: 10.1097/RLI.0b013e3181ee8b83 PMID: 20808233
26. Fan XZ, Wang LF, Guo YL, Tong HP, Li L, Ding J, et al. Experimental investigation of the penetration of ultrasound nanobubbles in a gastric cancer xenograft. Nanotechnology. 2013; 24(32).
27. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007; 50(4):472-83. PMID: 17448023
28. Elsasser-Beile U, Buhler P, Wolf P. Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen. Current Drug Targets. 2009; 10(2):118-25. PMID: 19199907
29. Foss CA, Mease RC, Cho SY, Kim HJ, Pomper MG. GCPII Imaging and Cancer. Current Medicinal Chemistry. 2012; 19(9):1346-59. PMID: 22304713
30. Sanna V, Pintus G, Bandiera P, Anedda R, Punzoni S, Sanna B, et al. Development of Polymeric Microbubbles Targeted to Prostate-Specific Membrane Antigen as Prototype of Novel Ultrasound Contrast Agents. Molecular Pharmaceutics. 2011; 8(3):748-57. doi: 10.1021/mp100360g PMID: 21545176
31. Muyldermans S, Baral TN, Retarnozzo VC, De Baetselier P, De Genst E, Kinne J, et al. Camelid immunoglobulins and nanobody technology. Vet Immunol Immunop. 2009; 128(1-3):178-83.
32. D'Huyvetter M, Xavier C, Caveliers V, Lahoutte T, Muyldermans S, Devoogdt N. Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer. Expert Opin Drug Del. 2014; 11(12):1939-54.
33. D'Huyvetter M, Vincke C, Xavier C, Aerts A, Impens N, Baatout S, et al. Targeted Radionuclide Therapy with A Lu-177-labeled Anti-HER2 Nanobody. Theranostics. 2014; 4(7):708-20. doi: 10.7150/thno.8156 PMID: 24883121
34. Broisat A, Hernot S, Toczek J, De Vos J, Riou LM, Martin S, et al. Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions. Circulation Research. 2012; 110(7):927-37. doi: 10.1161/CIRCRESAHA.112.265140 PMID: 22461363
35. Hernot S, Unnikrishnan S, Du ZM, Shevchenko T, Cosyns B, Broisat A, et al. Nanobody-coupled microbubbles as novel molecular tracer. Journal of Controlled Release. 2012; 158(2):346-53. doi: 10.1016/j.jconrel.2011.12.007 PMID: 22197777
36. Evazalipour M, Tehrani BS, Abolhassani M, Morovvati H, Omidfar K. Camel Heavy Chain Antibodies Against Prostate-Specific Membrane Antigen. Hybridoma. 2012; 31(6):424-9. doi: 10.1089/hyb.2012.0048 PMID: 23244321
37. Saerens D, Kinne J, Bosmans E, Wernery U, Muyldermans S, Conrath K. Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. Journal of Biological Chemistry. 2004; 279(50):51965-72. PMID: 15459193